Frontlight ResearchEarly access
TerminatedEarly phase 1
Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice
Key facts
- Who runs it
- Joshua A. Lile, Ph.D.
- Where
- Lexington, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Early phase 1
- People taking part
- 2 people enrolled
- Started
- 1 Mar 2023
- Ended
- 28 Mar 2025
- Type of study
- Interventional
- Treatments tested
- Drug Cue
- Money
- Withdrawal
- Remifentanil
- Record updated
- 30 March 2026
- Why it stopped
- Funding ended
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Individuals must meet criteria for moderate/severe opioid use disorder, report past month opioid misuse, and be physically dependent on short-acting opioids (e.g., heroin, hydromorphone, fentanyl), as evidenced by either urine sample positive for recent opioid use during each visit or if opioid negative, displaying frank withdrawal during screening
- History of intravenous opioid use
- Baseline O2 saturation of 95% or greater
- Between the ages of 18-50 years
- Female subjects must be using an effective form of birth control (e.g., birth control pills, surgical sterilization, IUD, cervical cap with a spermicide, or abstinence). Urine pregnancy tests will be conducted prior to sessions to ensure that female subjects do not participate if pregnant
- Able to speak and read English
- Otherwise healthy
Who cannot take part
- Contraindications for MRI scanning (e.g., pacemaker, metal implants, claustrophobia, or any other implanted medical device)
- Regular use of other medications, with the exception of hormone-based contraceptives for female subjects, daily multivitamins or short-term antibiotic prescriptions
- Seeking treatment for SUD or currently taking buprenorphine or methadone as the primary opioid of use
- History of, or current, clinically significant physical disease (e.g., respiratory disease [asthma, COPD, sleep apnea], impaired cardiovascular functioning, seizure disorder or CNS tumors) or current or past history of psychiatric disorder that would limit compliance in the studies, other than substance use disorder
- Meet diagnostic criteria for psychoactive substance use disorder for substances other than opioids (OUD subjects only) or nicotine/caffeine that would require detoxification (i.e., alcohol, benzodiazepines or barbiturates). Negative urine/breath samples for these substances, and the absence of withdrawal, will be required during screening
- Vision or hearing problems that would preclude completion of experimental tasks
- Poor venous access
- At risk for respiratory complications and have predictors of difficult bag mask ventilation (e.g., dentures, very full beard), in case emergency respiratory intervention is needed
Where in United States
- University of KentuckyLexington, United States
About the trial
What the trial wants to find out
The objective of this protocol is to use probabilistic choice tasks to determine the impact of withdrawal and drug cues on decision-making in individuals with opioid use disorder and physical opioid dependence.
The group in the trial
- Probabilistic Choice TaskTreatment being tested
Subjects with opioid use disorder complete a probabilistic concurrent choice task under opioid maintained and withdrawn conditions. Three sessions include a money-vs-money task and three sessions include a drug-vs-money task. Monetary reward value is $0.25 or $4.00. Task option visual cues for the money-vs-money versions are colored envelopes or opioid-associated and matched neutral cues. Drug is an active dose of remifentanil.
Treatment: Drug Cue, Money, Withdrawal, and Remifentanil
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Behavioral Effects of Drugs Inpatient 44: Neurobehavioral Mechanisms of Opioid Choice
- Record updated
- 30 March 2026